Biological characterization of TAK-901, an investigational, novel, multitargeted aurora B kinase inhibitor

Molecular Cancer Therapeutics

Volumn 12, Issue 4, 2013, Pages 460-470

  Farrell, Pamela ^a   Shi, Lihong ^a,e   Matuszkiewicz, Jennifer ^a   Balakrishna, Deepika ^a   Hoshino, Takashi ^c   Zhang, Lilly ^b   Elliott, Sarah ^a   Fabrey, Robyn ^a   Lee, Bumsup ^a,d   Halkowycz, Petro ^a   Sang, Biching ^b   Ishino, Seigo ^c   Nomura, Toshiyuki ^a   Teratani, Mika ^c   Ohta, Yoshikazu ^c   Grimshaw, Charles ^a   Paraselli, Bheema ^b,f   Satou, Takashi ^c   De Jong, Ron ^a  

^a Takeda San Diego Inc   (United States)

^b Takeda California   (United States)

^c TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^d Kolon Life Sciences Inc   (South Korea)

^e Quanticel Pharmaceuticals Inc   (United States)

^f Chemveda Life Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; AURORA B KINASE; AURORA KINASE INHIBITOR; CD135 ANTIGEN; DAUNORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; IRINOTECAN; TAK 901; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER REGRESSION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RAT; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARBOLINES; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HISTONES; HUMANS; KINETICS; MICE; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RATS; SULFONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876474597     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0657     Document Type: Article

References (45)

1. Carmena M, Earnshaw WC. The cellular geography of Aurora kinases. Nat Rev Mol Cell Biol 2003;4:842-54. (Pubitemid 37411723)
2. Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007;5:1-10.
3. Carmena M, Ruchaud S, Earnshaw WC. Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteins. Curr Opin Cell Biol 2009;21:796-805.
4. Meraldi P, Honda R, Nigg EA. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev 2004;14:29-36. (Pubitemid 38167474)
5. Karthigeyan D, Prasad SB, Shandilya J, Agrawal S, Kundu TK. Biology of Aurora A kinase: implications in cancer manifestation and therapy. Med Res Rev 2011;31:757-93.
6. Becker M, Stolz A, Ertych N, Bastians H. Centromere localization of INCENP-Aurora B is sufficient to support spindle checkpoint function. Cell Cycle 2010;9:1360-72.
7. Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003;161:267-80. (Pubitemid 36529846)
8. Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003;161:281-94. (Pubitemid 36529847)
9. Liu D, Lampson MA. Regulation of kinetochore-microtubule attachments by Aurora B kinase. Biochem Soc Trans 2009;37:976-80.
10. Girdler F, Gascoigne KE, Eyers PA, Hartmuth S, Crafter C, Foote KM, et al. Validating Aurora B as an anti-cancer drug target. J Cell Sci 2006;119:3664-75. (Pubitemid 44501870)
11. Pollard JR, Mortimore M. Discovery and development of aurora kinase inhibitors as anticancer agents. J Med Chem 2009;52:2629-51.
12. Lucena-Araujo AR, de Oliveira FM, Leite-Cueva SD, Dos Santos GA, Falcao RP, Rego EM. High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia. Leuk Res 2011;35:260-4.
13. Pohl A, Azuma M, Zhang W, Yang D, Ning Y, Winder T, et al. Pharma-cogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer. Pharmacogenomics J 2011;11:93-9.
14. Cheung CH, Coumar MS, Hsieh HP, Chang JY. Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs 2009;18:379-98.
15. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003;22: 451-64. (Pubitemid 36791899)
16. Barton VN, Foreman NK, Donson AM, Birks DK, Handler MH, Vibhakar R. Aurora kinase A as a rational target for therapy in glioblastoma. J Neurosurg Pediatr 2010;6:98-105.
17. Chen YJ, Chen CM, Twu NF, Yen MS, Lai CR, Wu HH, et al. Over-expression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients. Virchows Arch 2009;455:431-40.
18. Chieffi P, Cozzolino L, Kisslinger A, Libertini S, Staibano S, Mansueto G, et al. Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation. Prostate 2006; 66:326-33. (Pubitemid 43191232)
19. Kurai M, Shiozawa T, Shih HC, Miyamoto T, Feng YZ, Kashima H, et al. Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma. Hum Pathol 2005;36:1281-8. (Pubitemid 41682283)
20. Sorrentino R, Libertini S, Pallante PL, Troncone G, Palombini L, Bavetsias V, et al. AuroraB overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 2005;90:928-35. (Pubitemid 40279218)
21. Tatsuka M, Katayama H, Ota T, Tanaka T, Odashima S, Suzuki F, et al. Multinuclearity and increased ploidy caused by overexpression of the aurora-and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res 1998;58:4811-6. (Pubitemid 28503674)
22. Zeng WF, Navaratne K, Prayson RA, Weil RJ. Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme. J Clin Pathol 2007;60:218-21.
23. Dees EC, Infante JR, Burris HA, Astsaturov IA, Stinchcombe T, Liu H, et al. Phase I study of the investigational drug MLN8237, an Aurora A kinase (AAK) inhibitor, in patients (pts) with solid tumors. J Clin Oncol. 2010;28(Suppl.):15s: abstr 3010.
24. Macarulla T, Cervantes A, Elez E, Rodriguez-Braun E, Baselga J, Rosello S, et al. Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmaco-kinetics, and pharmacodynamics. Mol Cancer Ther 2010;9:2844-52.
25. Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A 2007;104: 4106-11. (Pubitemid 47181586)
26. Anderson K, Lai Z, McDonald OB, Stuart JD, Nartey EN, Hardwicke MA, et al. Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time. Biochem J 2009;420:259-65.
27. Boss DS, Witteveen PO, van der Sar J, Lolkema MP, Voest EE, Stockman PK, et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol 2011;22:431-7.
28. Hardwicke MA, Oleykowski CA, Plant R, Wang J, Liao Q, Moss K, et al. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther 2009;8:1808-17.
29. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007;13:3682-8. (Pubitemid 46955132)
30. Arbitrario JP, Belmont BJ, Evanchik MJ, Flanagan WM, Fucini RV, Hansen SK, et al. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Che-mother Pharmacol 2010;65:707-17.
31. Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007; 6:3158-68.
32. Curry J, Angove H, Fazal L, Lyons J, Reule M, Thompson N, et al. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283. Cell Cycle 2009;8:1921-9.
33. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeo-gun AO, Nakayama T, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-7. (Pubitemid 38667616)
34. Jani JP, Arcari J, Bernardo V, Bhattacharya SK, Briere D, Cohen BD, et al. PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther 2010;9:883-94.
35. McLaughlin J, Markovtsov V, Li H, Wong S, Gelman M, Zhu Y, et al. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol 2010;136:99-113.
36. Morrison JF, Walsh CT. The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 1988;61: 201-301.
37. Anderson K, Yang J, Koretke K, Nurse K, Calamari A, Kirkpatrick RB, et al. Binding of TPX2 to Aurora A alters substrate and inhibitor interactions. Biochemistry 2007;46:10287-95. (Pubitemid 350067622)
38. Bayliss R, Sardon T, Vernos I, Conti E. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol Cell 2003;12:851-62. (Pubitemid 37352779)
39. Honda R, Korner R, Nigg EA. Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 2003;14:3325-41. (Pubitemid 37013130)
40. Sessa F, Mapelli M, Ciferri C, Tarricone C, Areces LB, Schneider TR, et al. Mechanism of Aurora B activation by INCENP and inhibition by hesperadin. Mol Cell 2005;18:379-91. (Pubitemid 41350542)
41. Muraki M, Ohkawara B, Hosoya T, Onogi H, Koizumi J, Koizumi T, et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem 2004;279:24246-54. (Pubitemid 38725286)
42. Reilly JT. FLT3 and its role in the pathogenesis of acute myeloid leukaemia. Leuk Lymphoma 2003;44:1-7. (Pubitemid 36113823)
43. Moore AS, Blagg J, Linardopoulos S, Pearson AD. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia 2010;24: 671-8.
44. VanderPorten EC, Taverna P, Hogan JN, Ballinger MD, Flanagan WM, Fucini RV. The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtu-bule-targeted agents in a colon carcinoma model. Mol Cancer Ther 2009;8:930-9.
45. Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007;110:2034-40. (Pubitemid 47443920)